Company news

Oculis Holding AG news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts

November 3, 2026

Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation

November 2, 2026

Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit

October 29, 2026

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

October 22, 2026

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

October 22, 2026

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

October 20, 2026

Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki

October 19, 2026

Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease

October 19, 2026

Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

October 7, 2026

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

October 1, 2026

Oculis Announces Resignation of Lionel Carnot from Board of Directors

September 30, 2026

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

August 24, 2026

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis Position as an Emerging Leading Neuro-Ophthalmology Company

August 11, 2026

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

August 10, 2026

Oculis Reports Q2 2026 Financial Results and Provides Company Update

August 6, 2026

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

August 2, 2026

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

July 1, 2026

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

June 11, 2026

Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease

June 8, 2026

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

June 7, 2026

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

May 28, 2026

Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors

May 14, 2026

Oculis Reports Q1 2026 Financial Results and Provides Company Update

May 10, 2026

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

May 7, 2026

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

May 5, 2026

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

April 19, 2026

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

March 30, 2026

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

March 15, 2026

Oculis to Participate in Upcoming Investor Conferences

March 4, 2026

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update

March 3, 2026

Oculis Appoints Katie Kazem as Chief Legal Officer

February 16, 2026

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference

January 7, 2026

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

January 6, 2026

Oculis Reports Q3 2025 Financial Results and Provides Company Update

November 9, 2025

Oculis to Participate in Upcoming November Investor Conferences

November 4, 2025

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

October 29, 2025

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

October 13, 2025

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

October 5, 2025

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

September 21, 2025

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

September 3, 2025

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

August 31, 2025

Oculis to Participate in Upcoming September Investor Conferences

August 27, 2025

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors

August 24, 2025

Oculis Reports Q2 2025 Financial Results and Provides Company Update

August 20, 2025

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

August 11, 2025

Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

August 11, 2025

Oculis Upsized Loan Facility to Access up to CHF 100 million

July 31, 2025

Oculis Publishes Results of 2025 Annual General Meeting

June 4, 2025

Oculis to Participate in Upcoming June Investor Conferences

June 2, 2025

Oculis Publishes Invitation to the Annual General Meeting

May 8, 2025

Older news releases →

Decks

The 5 newest of 15 decks. Every deck is listed under its year.